BMYBristol-Myers Squibb Company
AI adoption · Q1 2026 earnings call
Health CarePiloting
4
extracted from this call
3 / 5
operational, no hard numbers
Not disclosed
no breakout in this call
AI was mentioned briefly in the context of R&D productivity initiatives, specifically as a tool to accelerate drug discovery and streamline clinical operations. Management cited AI as one component of a broader infrastructure investment alongside laboratory automation and workforce training. Two specific AI-enabled outcomes were referenced: a target of 50% faster lead molecule identification and a 30% reduction in development cycle times. A named partnership with Ferro for trial design efficiency was also disclosed.
Adopter
See full leaderboard →27/ 100
51
stage: piloting · max spec: 3
0
no quantified disclosure
35
1 scope
internal_use
4 AI mentions from this call.
Extracted verbatim from the BMY Q1 2026 earnings call transcript. Speaker, section, and specificity tier surfaced for each mention.
- T3Prepared remarks· CEO· Internal use
“In research and early development, target selection and molecule design can have an outsized impact on long-term value. We have set a target to reach lead molecule identification approximately 50% faster while applying greater rigor so that only the most differentiated molecules advance.”
— Christopher Boerner, BMY earnings call - T3Prepared remarks· CEO· Internal use
“In late development, we're using AI to streamline clinical operations, compress development time lines and enhanced quality oversight. Over time, we expect these efforts to deliver a 30% reduction in cycle times versus just a few years ago.”
— Christopher Boerner, BMY earnings call - T3Prepared remarks· CEO· Internal use
“Among others, we have ongoing partnerships with Ferro, enabling us to design trials more efficiently and [indiscernible] cost optimizer tool.”
— Christopher Boerner, BMY earnings callFerrocost optimizer tool - T2Prepared remarks· CEO· Internal use
“Underpinning these efforts are investments we are making in core R&D infrastructure, including broadening the use of AI tools together with laboratory automation and people trained in the right ways of working.”
— Christopher Boerner, BMY earnings call
What management wouldn’t quantify.
Analyst questions where management declined to share a specific number. The pattern of refusals is often as informative as the disclosures.
- No quantification of investment in AI tools or related R&D infrastructure spend.
- No disclosure of how many programs or trials are currently using AI tools.
- The 30% cycle time reduction target was not attributed to a specific baseline year or timeline for achievement.
- The 50% faster lead molecule identification target was presented as a goal, not a realized outcome — no current baseline or progress metrics disclosed.
- No analyst asked a direct question about AI strategy or investment, so no management responsiveness data on AI is available from Q&A.
- Partnership with Ferro described only qualitatively; no deal terms, scope, or financial commitment disclosed.
Compare with peers.
Other companies in the same sector and at the same AI adoption stage.
Same GICS sector, all stages
Independent research, direct to your inbox.
Live data tracking and analysis. Deep research that cuts through consensus. Evidence-backed insights.